286 related articles for article (PubMed ID: 21525465)
1. Incretin effects on β-cell function, replication, and mass: the human perspective.
Garber AJ
Diabetes Care; 2011 May; 34 Suppl 2(Suppl 2):S258-63. PubMed ID: 21525465
[No Abstract] [Full Text] [Related]
2. Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents.
Gallwitz B
Drugs; 2011 Sep; 71(13):1675-88. PubMed ID: 21902291
[TBL] [Abstract][Full Text] [Related]
3. GLP-1 receptor agonists: targeting both hyperglycaemia and disease processes in diabetes.
Holst JJ; Seino Y
Diabetes Res Clin Pract; 2009 Jul; 85(1):1-3. PubMed ID: 19299027
[No Abstract] [Full Text] [Related]
4. Investigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide.
González C; Beruto V; Keller G; Santoro S; Di Girolamo G
Expert Opin Investig Drugs; 2006 Aug; 15(8):887-95. PubMed ID: 16859392
[TBL] [Abstract][Full Text] [Related]
5. The effects of glucagon-like peptide-1 on the beta cell.
Vilsbøll T
Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():11-8. PubMed ID: 19878257
[TBL] [Abstract][Full Text] [Related]
6. Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors.
Verspohl EJ
Pharmacol Ther; 2009 Oct; 124(1):113-38. PubMed ID: 19545590
[TBL] [Abstract][Full Text] [Related]
7. Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting.
Garber AJ
Am J Manag Care; 2010 Aug; 16(7 Suppl):S187-94. PubMed ID: 20809667
[TBL] [Abstract][Full Text] [Related]
8. Integrating incretin-based therapy into type 2 diabetes management.
Brunton SA
J Fam Pract; 2013 Jun; 62(6 Suppl CME):S1-8. PubMed ID: 23828807
[No Abstract] [Full Text] [Related]
9. Combination pharmacotherapy with incretins: what works best and when?
Over RK; Ratner RE
Curr Diab Rep; 2008 Oct; 8(5):361-7. PubMed ID: 18778584
[TBL] [Abstract][Full Text] [Related]
10. [Incretin-based therapy for treating patients with type 2 diabetes].
Jermendy G
Orv Hetil; 2011 Nov; 152(48):1931-40. PubMed ID: 22071295
[TBL] [Abstract][Full Text] [Related]
11. Incretins: their physiology and application in the treatment of diabetes mellitus.
Tasyurek HM; Altunbas HA; Balci MK; Sanlioglu S
Diabetes Metab Res Rev; 2014 Jul; 30(5):354-71. PubMed ID: 24989141
[TBL] [Abstract][Full Text] [Related]
12. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.
Iepsen EW; Torekov SS; Holst JJ
Expert Opin Pharmacother; 2014 Dec; 15(17):2487-500. PubMed ID: 25260877
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
Pinelli NR; Hurren KM
Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
[TBL] [Abstract][Full Text] [Related]
14. [Incretin related agents for treatment of diabetes mellitus].
Miyagawa J; Miuchi M; Nanba M
Nihon Naika Gakkai Zasshi; 2009 Apr; 98(4):809-16. PubMed ID: 19472544
[No Abstract] [Full Text] [Related]
15. [The value of incretin based therapies].
Gallwitz B
Dtsch Med Wochenschr; 2009 May; 134(20):1062-6. PubMed ID: 19421931
[No Abstract] [Full Text] [Related]
16. GLP-1 agonists in type 1 diabetes.
Pettus J; Hirsch I; Edelman S
Clin Immunol; 2013 Dec; 149(3):317-23. PubMed ID: 23643354
[TBL] [Abstract][Full Text] [Related]
17. Distinguishing among incretin-based therapies. Patient education and self-management.
Campbell RK; Cobble ME; Reid TS; Shomali ME
J Fam Pract; 2010 Sep; 59(9 Suppl 1):S28-30. PubMed ID: 20824237
[TBL] [Abstract][Full Text] [Related]
18. [Twice-daily and weekly exenatide: clinical profile of two pioneer formulations in incretin therapy].
Lecube A; Bueno M; Suárez X
Med Clin (Barc); 2014 Sep; 143 Suppl 2():23-7. PubMed ID: 25437462
[TBL] [Abstract][Full Text] [Related]
19. [Protective effects of glucagon-like peptide-1 on beta-cells: preclinical and clinical data].
Consoli A; Di Biagio R
G Ital Cardiol (Rome); 2011 Dec; 12(12 Suppl 2):5-9. PubMed ID: 22158421
[TBL] [Abstract][Full Text] [Related]
20. Incretin effect: GLP-1, GIP, DPP4.
Kazafeos K
Diabetes Res Clin Pract; 2011 Aug; 93 Suppl 1():S32-6. PubMed ID: 21864749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
